Evidence map›Paper›PMID 42863370›Full record

ArticleEBioMedicine2026

Sustained type I interferon activity and N-antigenemia form a vicious cycle during severe COVID-19.

William Mouton, Kahina Saker, Priscille Franc, Marine Mommert-Tripon, Guy Oriol, Laurence Generenaz, Valérie Cheynet, Antonin Bal, Léa Pons, Brice Wittmann and 25 more

Abstract read
In one paragraph

Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

William MoutonCIRI, Centre International de Recherche en Infectiologie, Inserm U1111, Université Claude Bernard Lyon 1, Université de Saint-Etienne, CNRS, UMR5308, ENS de Lyon, Lyon, F-69007, France; Joint Research Unit Hospices Civils de Lyon-bioMérieux, Lyon Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, F-69495, France.
Kahina SakerCIRI, Centre International de Recherche en Infectiologie, Inserm U1111, Université Claude Bernard Lyon 1, Université de Saint-Etienne, CNRS, UMR5308, ENS de Lyon, Lyon, F-69007, France; Joint Research Unit Hospices Civils de Lyon-bioMérieux, Lyon Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, F-69495, France.
Priscille FrancCIRI, Centre International de Recherche en Infectiologie, Inserm U1111, Université Claude Bernard Lyon 1, Université de Saint-Etienne, CNRS, UMR5308, ENS de Lyon, Lyon, F-69007, France; Joint Research Unit Hospices Civils de Lyon-bioMérieux, Lyon Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, F-69495, France.
Marine Mommert-TriponJoint Research Unit Hospices Civils de Lyon-bioMérieux, Lyon Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, F-69495, France.
Guy OriolJoint Research Unit Hospices Civils de Lyon-bioMérieux, Lyon Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, F-69495, France.
Laurence GenerenazJoint Research Unit Hospices Civils de Lyon-bioMérieux, Lyon Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, F-69495, France.
Valérie CheynetJoint Research Unit Hospices Civils de Lyon-bioMérieux, Lyon Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, F-69495, France.
Antonin BalInfective Agents Institute, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, F-69004, France.
Léa PonsJoint Research Unit Hospices Civils de Lyon-bioMérieux, Lyon Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, F-69495, France.
Brice WittmannJoint Research Unit Hospices Civils de Lyon-bioMérieux, Lyon Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, F-69495, France.
David BussyJoint Research Unit Hospices Civils de Lyon-bioMérieux, Lyon Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, F-69495, France.
Paul BastardSt. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, 10065, USA; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Enfants Malades Hospital, AP-HP, Paris, F-75015, France; Université Paris Cité, Institut Imagine, Paris, F-75015, France; Pediatric Hematology-Immunology and Rheumatology Unit, Necker Enfants Malades Hospital, AP-HP, Paris, F-75015, France.
Jean-Laurent CasanovaSt. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, 10065, USA; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Enfants Malades Hospital, AP-HP, Paris, F-75015, France; Université Paris Cité, Institut Imagine, Paris, F-75015, France; Department of Pediatrics, Necker Enfants Malades Hospital, AP-HP, Paris, F-75015, France.
Sarah SebaiCIRI, Centre International de Recherche en Infectiologie, Inserm U1111, Université Claude Bernard Lyon 1, Université de Saint-Etienne, CNRS, UMR5308, ENS de Lyon, Lyon, F-69007, France.
Amel ChebelCIRI, Centre International de Recherche en Infectiologie, Inserm U1111, Université Claude Bernard Lyon 1, Université de Saint-Etienne, CNRS, UMR5308, ENS de Lyon, Lyon, F-69007, France.
Fabrice ChatonnetCIRI, Centre International de Recherche en Infectiologie, Inserm U1111, Université Claude Bernard Lyon 1, Université de Saint-Etienne, CNRS, UMR5308, ENS de Lyon, Lyon, F-69007, France.
Dominique CostagliolaUniversité de la Sorbonne, Inserm, Institut Pierre-Louis d'Épidémiologie et de Santé Publique, Paris, F-75006, France.
Jose ArribasDepartment of Internal Medicine, CIBER of Infectious Diseases (CIBERINFEC), Hospital La Paz Institute for Health Research (IdiPAZ), La Paz University Hospital, Madrid, S-28046, Spain.
Hans-Kittil ViermyrSection for Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, N-0372, Norway; Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, N-0372, Norway; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, N-0372, Norway.
Julien PoissyIntensive Care Unit, Lille University Hospital / UGSF - Glycobiology in Fungal Pathogenesis and Clinical Applications INSERM U1285 - CNRS - UMR 8576, Université de Lille, Lille, F-59000, France.
Aleksander Rygh HoltenFaculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, N-0372, Norway; Department of Acute Medicine, Oslo University Hospital, Oslo, N-0424, Norway.
Aliou BaldéUniversité de la Sorbonne, Inserm, Institut Pierre-Louis d'Épidémiologie et de Santé Publique, Paris, F-75006, France.
Emmanuel RouxUniversité de Lyon, Université Claude Bernard Lyon 1, INSA-Lyon, CNRS, INSERM, CREATIS UMR 5220, U1294, Villeurbanne, F-69100, France.
Inge C OlsenDepartment of Research Support for Clinical Trials, Oslo University Hospital, Oslo, N-0424, Norway.
Karen Brengel-PesceJoint Research Unit Hospices Civils de Lyon-bioMérieux, Lyon Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, F-69495, France.
Sylvie PonsJoint Research Unit Hospices Civils de Lyon-bioMérieux, Lyon Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, F-69495, France.
Cécile BarnelJoint Research Unit Hospices Civils de Lyon-bioMérieux, Lyon Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, F-69495, France.
Bouchra MokdadJoint Research Unit Hospices Civils de Lyon-bioMérieux, Lyon Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, F-69495, France.
Florent WalletIntensive Care Unit, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, F-69004, France; INSERM U1290, Université Claude Bernard Lyon 1, Research on Healthcare Performance (RESHAPE), Lyon, F-69008, France.
Laurent GenestierCIRI, Centre International de Recherche en Infectiologie, Inserm U1111, Université Claude Bernard Lyon 1, Université de Saint-Etienne, CNRS, UMR5308, ENS de Lyon, Lyon, F-69007, France.
Olivier TerrierCIRI, Centre International de Recherche en Infectiologie, Inserm U1111, Université Claude Bernard Lyon 1, Université de Saint-Etienne, CNRS, UMR5308, ENS de Lyon, Lyon, F-69007, France.
Marius TrøseidSection for Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, N-0372, Norway; Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, N-0372, Norway.
Jean-Christophe RichardUniversité de Lyon, Université Claude Bernard Lyon 1, INSA-Lyon, CNRS, INSERM, CREATIS UMR 5220, U1294, Villeurbanne, F-69100, France; Intensive Care Unit, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, F-69004, France.
Sophie Trouillet-AssantCIRI, Centre International de Recherche en Infectiologie, Inserm U1111, Université Claude Bernard Lyon 1, Université de Saint-Etienne, CNRS, UMR5308, ENS de Lyon, Lyon, F-69007, France; Joint Research Unit Hospices Civils de Lyon-bioMérieux, Lyon Sud Hospital, Hospices Civils de Lyon, Pierre-Bénite, F-69495, France. Electronic address: sophie.trouillet-assant@chu-lyon.fr.
Interfericus and BarisolidAct study groups

Funding

Inborn errors of immunity in patients with life-threatening COVID-19R01AI163029 · NIAID · ROCKEFELLER UNIVERSITY · PI CASANOVA, JEAN-LAURENT, ZHANG, QIAN · 2021 to 2025
$3.7M
NIAID NIH HHS R01 AI163029
6 · The paper itself

Abstract

backgroundAlthough antigenemia is associated with poor outcomes in respiratory viral infections, the underlying mechanisms driving viral bloodstream dissemination remain not fully understood. Herein, we aimed to characterise SARS-CoV-2 nucleocapsid (N)-antigenemia kinetics in patients with severe COVID-19. We also sought to identify host and viral determinants associated with viral dissemination through a multiparametric integrated analysis and assess the associated risk of death.

methodsThis observational study included hospitalised patients with severe COVID-19 across three independent cohorts (discovery, n = 66; confirmation, n = 137; validation, n = 27), used respectively for identification, replication, and validation of findings, along with patients with mild COVID-19 and with severe influenza infection, as a disease severity and non-COVID-19 control group. From blood and nasal samples, N-antigenemia levels were analysed in relation to 45 host/viral parameters. Multivariable logistic regression was performed to assess the association with in-hospital mortality. Single-cell RNA sequencing was used to identify host determinants, and in vitro primary human airway epithelial models were used to assess epithelial barrier integrity and viral translocation.

findingsAcross cohorts, we observed a significantly higher detection rate and concentration of N-antigenemia in patients with severe COVID-19 at admission compared to those with mild COVID-19 or controls (fold change [FC] >54.7, p < 0.001 [Kruskal-Wallis, Dunn post-hoc]). Type-I interferon (IFN-I) activity was the strongest correlate of N-antigenemia (ρ = 0.72, p.adj < 0.001 [Spearman, Benjamini-Hochberg]), and longitudinal analyses revealed a strong positive sigmoidal relationship (p < 0.001 [approximate Wald test]). Patients with severe COVID-19 with neutralising autoantibodies against IFN-I lacked detectable N-antigenemia, further supporting a link between systemic viral dissemination and IFN-I activity. Single-cell RNA sequencing showed higher expression of interferon-stimulated genes in monocytes and dendritic cells in patients with a high N-antigenemia level. Furthermore, high N-antigenemia at hospital admission was independently associated with an increased risk of death (aOR 2.6, 95% CI 1.0-6.7; p = 0.042 [Wald test]). Finally, we demonstrated that prolonged IFN-I exposure in vitro appears to impair epithelial barrier integrity.

interpretationThese findings suggest that sustained IFN-I activity is associated with systemic viral dissemination and epithelial barrier dysfunction in patient with severe COVID-19. The concordance between clinical observations and in vitro data supports a potential link between prolonged IFN-I responses and these processes, although causality remains to be established. These results highlight the potential importance of the timing and duration of IFN-I immunity and warrant further investigation of its clinical relevance.

fundingAgence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS), ANRS Maladies Infectieuses Émergentes (ANRS MIE), Agence Nationale de la Recherche (ANR), Institut National de la Santé et de la Recherche Médicale (INSERM), European Union Horizon 2020 Research and Innovation Programme, CAPNET, and Klinbeforsk.

Indexed as

Innate immune responseN-antigenemiaSARS-CoV-2Severe diseaseType I IFN

Identifiers

PMID42863370
PMCPMC13682480

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.